MedTrace Logo

Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes

NCT05233592 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2023-05-17

No results posted yet for this study

Summary

Vaccines for COVID-19 are an essential part of combating the coronavirus pandemic. Vaccines "prime" the immune system against an invader (in this case the SARS-CoV-2 virus) by causing a temporary increased immune or inflammatory response. Inflammation can temporarily increase sugar levels and/or insulin requirements among patients with diabetes. The purpose of this study is to investigate whether the "booster" COVID-19 vaccine dose causes temporarily increased sugar levels and/or insulin dose requirements among patients with Type 1 Diabetes (T1D).

Conditions

Interventions

DEVICE

CGM

Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.

Sponsors & Collaborators

Principal Investigators

  • Andrew P Demidowich, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-08
Primary Completion
2023-04-04
Completion
2023-04-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05233592 on ClinicalTrials.gov